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Impact of fecal carriage of extended-spectrum beta-lactamase 
producing Enterobacteriaceae   on the outcomes of transrectal needle 
biopsies of the prostate
Geniş spektrumlu beta laktamaz üreten Enterobacteriaceae taşıyıcılığının prostatın transrectal 
iğne biyopsisi sonuçlarına etkisi
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Introduction
Extended-spectrum beta-lactamase producing 
Enterobacteriaceae (ESBL-PE) carriage  is increasing 
in the community, especially in elderly males in all over 
the world [1,2]. Intestinal colonization is a major factor 
for transmission in the community [3]. Valverde et al. have 
pointed out that the prevalence of  ESBL-PE infections has 
increased dramatically during the last decade in Spain [2]. 
Moreover, an increase in the fecal carriage  of E.coli that 
produce ESBL from 0.1% in 2002 to 1.7% in 2005 has been 
noted in the USA [4]. The incidence of fecal carriage of 
ESBL-PE in Turkey was 15.2% in a recent study [5]. 
Transrectal ultrasound guided needle biopsy of the 
prostate (TRNBP) is used by urologists to diagnose and 
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ABSTRACT
Objective: This study aimed to address the prevalence,  the risk 
factors and the results of fecal carriage of extended-spectrum  beta-
lactamase producing Enterobacteriaceae (ESBL-PE) in patients 
who had  undergone   transrectal needle biopsy of the prostate 
(TRNBP). 
Patients and Methods: A total of 143 patients who had 
undergone TRNBP were included. Of these, 33(23%) had fecal 
carriage of ESBL-PE. The mean age of the patients was 62 ±  7.5 
(43-81) years. 
Results: A univariate analysis showed that quinolone or other 
antibiotic use within the last 2 months, prostatitis, and diabetes 
mellitus (DM) were significantly associated with  the presence of 
ESBL-PE. A multivariate analysis showed that quinolone use within 
the past  2 months (OR: 4.865; CI: 1.45-16.1), and DM (OR: 4.04; 
CI: 1.64-10)  were found to be significant. Development of dysuria 
(p<0.001), fever (p=0.046) and chills  (p=0.002)  after TRNBP 
were shown to be related to  the presence of ESBL-PE . There was 
no asymptomatic bacteriuria and sepsis, the rate of symptomatic 
urinary tract infection was 19%. 
Conclusion: This study showed that pre-biopsy risk factors 
for the presence of  ESBL-PE were quinolone or other antibiotic 
use within the last 2 months and presence of  DM. Changing 
prophylactic regimens should not be recommended due to the low 
rate of severe complications.
Key words: Extended-spectrum beta-lactamases, Transrectal 
needle biopsy of the prostate, Fecal carriage, Infection
ÖZET
Amaç: Bu çalışmada,  transrektal prostat biyopsisi (TRPB) 
öncesi,  hastalarda dışkıda geniş spektrumlu beta-laktamaz üreten 
Enterobacteriaceae (GSBL-ÜE) taşıyıcılığı oranları, risk faktörleri 
ve sonuçları gösterilmesi amaçlanmıştır. 
Hastalar ve Yöntem: Toplam 143 TRPB yapılan hasta 
çalışmaya alınmıştır. Bunların 33(%23)’ünde GSBL-ÜE taşıyıcılığı 
bulunmuştur. Ortalama hasta yaşı 62 ± 7,5 (43-81)dir. 
Bulgular: Tek değişkenli analizle son 2 ayda kinolon veya 
başka bir antibiyotik kullanımı, prostatit ve diabetes mellitus 
(DM) GSBL-ÜE taşıyıcılığı ile ilşkili bulunmuştur. Çok değişkenli 
analiz, son 2 ayda kinolon kullanımı (OR: 4,865; CI: 1,45-16,1), 
ve DM (OR: 4,04; CI: 1,64-10) varlığını önemli faktörler olarak 
göstermiştir. TRPB sonrası disüri (p<0,001), ateş (p=0,046) ve 
üşüme-titreme (p=0,002) gelişmesi GSBL-ÜE taşıyıcılığı ile ilişkili 
bulunmuştur. Asemptomatik bakteriüri ve sepsis saptanmamıştır. 
Semptomatik üriner sistem infeksiyon oranı %19’dur. 
Sonuç: Bu çalışma GSBL-ÜE taşıyıcılığı için biyopsi öncesi risk 
faktörlerinin son 2 ayda kinolon veya diğer antibiyotik kullanımı ve 
DM varlığı olduğunu göstermiştir. Ciddi infektif komplikasyonların 
düşük oranda olması nedeniyle profilaksi rejimlerinin değiştirilmesi 
önerilmemektedir.
Anahtar kelimeler: Geniş spektrumlu beta-laktamaz,  Transrektal 
prostat iğne biopsisi, Fekal taşıyıcılık, Enfeksiyon
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stage prostate cancers. Even though it is accepted as a safe 
procedure, complications such as bleeding and infection can 
occur. TRNBP performed without prophylactic antibiotic 
administration is related to subclinical temporary bacteremia 
in 73-100% of patients and to symptomatic urinary tract 
infections (UTIs) in up to 87% of patients [6]. In a Swedish 
study, the rates of symptomatic UTI and sepsis were reported 
as 0.9% and 0.001% respectively among patients using single 
dose fluoroquinolone prophylaxis [7]. Major risk factors for 
development of UTI after prostate biopsies were defined 
as use of corticosteroids, presence of urinary catheters, 
diabetes mellitus (DM) and prostatitis [8]. We investigated 
the prevalence of fecal carriage of ESBL-PE  in patients 
undergoing TRNBP, analyzed the risk factors for ESBL 
before biopsy and described the outcome of the patients.
Patients and Methods 
One hundred and forty-three patients who applied for TRNBP 
at  the Department of Infectious Diseases and Clinical 
Microbiology, School of Medicine, Marmara University 
between October 2008 and February 2010 were recruited. No 
restriction was applied for the use of prophylactic antibiotics, 
which were mainly quinolones, fosfomycin, aminoglycosides 
and cephalosporins. The rectal swabs containing fecal 
material were obtained before the biopsy and were spread 
onto two MacConkey agar plates, each supplemented 
with 1 µg/ml cefotaxime or 1 µg/ml ceftazidime. At least 
two colonies with distinct morphotype were selected for 
subsequent characterization. Combined disc method was 
used to verify the ESBL production according to the Clinical 
and Laboratory Standard Institute (CLSI) guidelines (CLSI, 
M100-S18, Wayne, PA, USA, 2008). Urine cultures were 
obtained before, 3 and 14 days after the biopsy. Symptomatic 
urinary tract infection was defined as  a culture positive on 
the third day for any pathogen and any existing urinary tract 
symptoms. Patients with 38º C fever after TRNBP were 
identified as febrile.  Blood cultures were obtained from the 
febrile patients. 
Statistical Analysis
The relationship between the fecal carriage of ESBL-PE and 
post biopsy complications was analyzed using the software 
SPSS for Windows, version 15.0; (SPSS Inc, Chicago, 
Illinois, USA). Data obtained were presented as mean ± 
SD, controlled for normal distributions by the Kolmogorov-
Smirnov test and compared by the unpaired Student’s t-test 
when the distribution appeared normal. Categorical data 
between two or more groups were compared by the Pearson 
χ 2 test. The effect of ESBL on the clinical outcomes was 
assessed by a multivariate analysis model, where the 
dependent variable was kept constant while the independent 
variables changed according to the course of the follow up. 
A p value of <0.05 was accepted as statistically significant. 
Results
Of the 143 patients enrolled, 33 (23%) had fecal carriage of 
ESBL-PE. The mean age of the patients enrolled in the study 
was 62 ± 7.5 (43-81) years. Follow-up urine cultures could 
be obtained from 103 (72 %) of the patients on the  3rd day 
and from 70 (49%) patients on the 14th day. Bacteriuria was 
detected in 16 (15.5 %) patients on the 3rd day, there were 
no growths in the urine cultures for the 14th day. Prophylaxis 
of patients before biopsy was not interfered. Eighty one 
(56.5%) of patients were given prophylactic fluoroquinolone, 
62 (43.5%) of patients were given cefuroxime axetil.
In the univariate analysis, quinolone or other antibiotic 
use within the last 2 months, prostatitis, and DM were found 
to be significantly associated with the fecal carriage of the 
ESBL-PE  (Table I). In the multivariate analysis, quinolone 
Table I. Univariate analysis of the risk factors for ESBL producing 
Enterobacteriaceae carriage before biopsy
ESBL (+) ESBL (-) p
Quionolone use within the last  
2 months
15/33 (45%) 12/110 (11%) <0.0001
Antibiotic use within the last  
2 months
22/33 (67%) 31/110 (28%) <0.0001
Prostatitis 9/33 (27%) 12/110 (11%) 0.020
Hospitalization within the past  
3 months
2/33 (6%) 2/110 (2%) 0.195
Urethral catheterization within 
the past 2 months
1/33 (3%) 0/110 0.231
DM 8/33 (24%) 7/110 (6%) 0.003
use within the previous 2 months (OR: 4.865; CI: 1.45-16.1), 
and DM (OR: 4.04; CI: 1.64-10)  was found to be significantly 
associated with the fecal carriage of ESBL-PE. 
Development of dysuria (p<0.001), fever (p=0.046) and 
chills (p=0.002) after TRNBP were found to be related with 
ESBL the fecal carriage of ESBL-PE . Symptoms such as 
suprapubic tenderness, hesitancy and frequency were not 
found to be related with ESBL-PE.
Discussion
The increase in ESBL-PE  infections after prostate biopsies 
has prompted us to elucidate the possible risk factors for such 
infections. Both an increase in infections and the fecal carriage 
of ESBL-PE has been reported in recent studies [2, 9]. Even 
though a significant  number of epidemiological studies 
have questioned the fecal carriage of ESBL-PE in healthy 
individuals,  not much information has been reported about 
the specific subset of patients who received the  TRNBP 
procedure. In our study,  the fecal carriage of ESBL-PE  in 
this specific group of patients was investigated. 
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The incidence of fecal carriage of ESBL-PE  (in 23 % of 
the patients) in our study was one of the highest among other 
recent studies. The rate of fecal carriage of ESBL-PE was 
reported as 7.3% in Tunisia, which is another Mediterranean 
country [10].  The prevalences were reported as relatively 
low in Spain (6%) [11]. However, several studies have 
reported  higher than Tunisia but lower than our results 
(16.7%, 15.6%) [9, 12]. In a study from Turkey, the rate 
of fecal carriage of ESBL-PE  was reported as 15.2% [5], 
whereas in our study this rate was found to be much higher.
We did not observe an increased rate of asymptomatic 
bacteriuria after the biopsy in patients with ESBL-PE 
carriage. In our study the symptomatic urinary tract infection 
rate was 19% with no sepsis after TRNBP. The rate of sepsis 
was shown to be between 0.5-2% in various studies from 
different countries [13]. Our results might be related with the 
limited number of patients in the study population.
Antibiotic prophylaxis for TRNBP should be given for 
reducing infectious complications, although the choice of 
antibiotic is not clear. Despite increasing numbers of reports 
suggesting an increase of urinary tract infections (UTIs) 
with ESBL producing E.coli after TRNBP, it is difficult 
to recommend a major change in the current prophylaxis 
practice, mainly a single dose   fluoroquinolone  to reduce 
the number of such infections since the number of severe 
infective complications is still low, as in our study.
Our results also demonstrate  an independent correlation 
between the fecal carriage of ESBL-PE and the presence of 
DM as in previous reports [14,15]. This might be secondary 
to a high rate of hospitalizations or to antibiotic usage in 
diabetic patients [14]. Further large scale prospective studies 
in diabetics are needed to clarify this relation.
Conclusion
In conclusion, the fecal carriage of ESBL-PE was detected 
in 23 % of patients undergoing TRNBP, which is one of the 
highest rates in the literature. Pre-biopsy risk factors for the 
fecal carriage of ESBL-PE  were quinolone or other antibiotic 
use within the last 2 months and the presence of DM. A 
change in prophylactic regimens cannot be recommended 
due to low rate of severe complications in our study.
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